Search alternatives:
significantly improved » significantly increased (Expand Search)
improved decrease » improved urease (Expand Search), marked decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
Showing 21 - 40 results of 8,048 for search '(( significantly ((mean decrease) OR (teer decrease)) ) OR ( significantly improved decrease ))', query time: 0.63s Refine Results
  1. 21
    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups.

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 22
    Time course of best-corrected visual acuity (BCVA) in all eyes.

    Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 23
    Annual number of outpatient visits in recurrence and non-recurrence groups.

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 24
    Time course of central retinal thickness (CRT) in all eyes.

    Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 25
    Annual treatment frequencies in all eyes.

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 26
    Annual treatment frequencies in recurrence and non-recurrence groups.

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 27
    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups.

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 28
    Preoperative background characteristics of the patients.

    Preoperative background characteristics of the patients. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 29
    Comparison of mean days of wound healing across different wound types for wounds healed in more than 3 months durations (2022 and 2023).

    Comparison of mean days of wound healing across different wound types for wounds healed in more than 3 months durations (2022 and 2023). by Heba Tallah Mohammed (2822432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 30
    Comparison of mean days of wound healing across different wound types for wounds healed in less than 3 months durations (2022 and 2023).

    Comparison of mean days of wound healing across different wound types for wounds healed in less than 3 months durations (2022 and 2023). by Heba Tallah Mohammed (2822432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 31
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 32
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 33
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 34
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 35
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 36
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 37
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 38
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 39
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 40
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: